EGFR, epidermal growth factor receptor, 1956

N. diseases: 1394; N. variants: 183
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE It is used in the treatment of non-small cellular lung carcinoma and spares wild-type EGFR. 31539712 2020
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 GeneticVariation disease BEFREE However, patients lacking EGFR mutations are not sensitive to EGFR-TKI treatment and the emergence of secondary resistance poses new challenges for the targeted therapy of lung cancer. 31777985 2020
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 GeneticVariation disease BEFREE PET/CT images of lung cancer patients were obtained from public databases and used to establish two datasets, respectively to classify histological subtypes (156 adenocarcinomas and 32 squamous cell carcinomas) and EGFR mutation status (38 mutant and 100 wild-type samples). 31659591 2020
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE We investigated whether A2B receptor is involved in EGFR translocation and DNA damage response (γH2AX/53BP1 focus formation) of lung cancer cells by means of immunofluorescence studies. 31678144 2020
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE Besides being a predictive biomarker of response to immunotherapy in lung cancer in general, programmed death-ligand 1 (PD-L1) is not so well correlated with treatment outcomes of lung adenocarcinoma (ADC) harbouring epidermal growth factor receptor (EGFR) mutations, as reported studies are inconclusive and seldom addressed the issues of response to treatment and resistance. 31760310 2020
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE There are numerous biomarkers for the lung cancer such as EGFR, CEA, CYFRA 21-1, ENO1, NSE, CA 19-9, CA 125 and VEGF. 31514848 2020
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE The role of serum tumor markers (STMs) in the modern management of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations in lung cancer remains poorly described. 31707279 2020
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE Of the 9 patients analysed, 7 carried oncogene-addicted LC (4 EGFR, 1 B-RAF and 2 ALK) and five out of 7 carried BRCA mutations. 31662533 2020
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE Several growth related genes such as EGFR and VEGF as well as tumour suppressor genes such as p53 have been implicated in LC pathogenesis and progression. 31770191 2020
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 GeneticVariation disease BEFREE Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/EGFR mutation double-positive lung cancer. 31782583 2020
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE <b>Conclusions:</b> In conclusion, metformin may potentially enhance the therapeutic effect and increase survival in type 2 DM patients with lung cancer receiving EGFR-TKI therapy. 31409137 2020
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors. 30870512 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 GeneticVariation disease BEFREE The aim of this study was to evaluate the adequacy of EBUS-TBNA in providing adequate size specimens for EGFR, ALK and ROS1 genetic mutation analysis in patients with adenocarcinoma or not otherwise specified (NOS) lung cancer. 30582673 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 GeneticVariation disease BEFREE Erlotinib is a targeted anticancer therapy used for treating epidermal growth factor receptor (EGFR) mutation positive lung cancer in advanced stage as well as for other malignancies. 30679984 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 GeneticVariation disease BEFREE Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in ALK-positive lung cancer: Comparison with EGFR-mutated lung cancer. 30580903 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE <b>Purpose:</b> Drug resistance is a major challenge for epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) treatment of lung cancer. 31417255 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 GeneticVariation disease BEFREE The coexistence of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement in patients with multifocal lung adenocarcinomas (LUAC) constitutes a rare molecular subtype of lung cancer. 31138506 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 GeneticVariation disease BEFREE To determine the sensitivity of MASS-PCR, 717 lung cancer specimens, 61 formalin-fixed paraffin-embedded (FFPE) tissues, and 656 fresh reaction tissues are collected and undergo mutation detection of lung cancer driver genes (EGFR, KRAS, BRAF, HER2, MET, ALK, and ROS1). 30677225 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE In conclusion, the identified DEGs, particularly the hub genes, strengthen the understanding of the development and progression of lung cancer, and certain genes (including advanced glycosylation end‑product specific receptor and epidermal growth factor receptor) may be used as candidate target molecules to diagnose, monitor and treat lung cancer. 30664219 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 GeneticVariation disease BEFREE We searched four databases for all original articles on family history of malignancy and EGFR mutation status in lung cancer published up to July 2018. 31703574 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE The treatment of lung cancer has also evolved with the introduction of several lines of tyrosine kinase inhibitors in patients with EGFR, ALK, ROS1, and NTRK mutations. 31378236 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 GeneticVariation disease BEFREE The purpose of this review is to: 1) analyze various preanalytical, analytical, and postanalytical factors influencing ICC results; 2) discuss measures for validation of ICC protocols; and 3) summarize published data on predictive ICC for ALK, ROS1, EGFR gene alterations and PD-L1 expression on lung cancer cytology. 31050216 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 GeneticVariation disease BEFREE A 79-year-old woman had disease progression during third-line treatment with osimertinib for an EGFR L858R/T790M-mutant lung cancer. 31254668 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE Epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma oncogene (KRAS) signaling pathways play a critical role in the proliferation and progression of various cancers, including lung cancer. 30132854 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 GeneticVariation disease BEFREE Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib. 30797494 2019